# A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

> **NCT07188805** · PHASE3 · RECRUITING · sponsor: **Bayer** · enrollment: 111 (estimated)

## Conditions studied

- Left Ventricular Systolic Dysfunction
- Heart Failure (Pediatric)

## Interventions

- **DRUG:** Finerenone (Kerendia, BAY94-8862)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07188805
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-19
- **Primary completion:** 2029-11-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188805, "A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07188805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*